A Computational Approach for Molecular Characterization of Covaxin (BBV152) and Its Ingredients for Assessing Its Efficacy against COVID-19

SARS-CoV-2 vaccination is a life-saving strategy for the entire population living in this pandemic. Several vaccines were developed using different platforms such as nucleic acids, viral vectors recombinant proteins, live attenuated, and inactivated virus modalities, etc. Although immunogenicity and...

Full description

Bibliographic Details
Main Authors: Atala B. Jena, Asim K. Duttaroy
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Future Pharmacology
Subjects:
Online Access:https://www.mdpi.com/2673-9879/2/3/21
_version_ 1797465242055213056
author Atala B. Jena
Asim K. Duttaroy
author_facet Atala B. Jena
Asim K. Duttaroy
author_sort Atala B. Jena
collection DOAJ
description SARS-CoV-2 vaccination is a life-saving strategy for the entire population living in this pandemic. Several vaccines were developed using different platforms such as nucleic acids, viral vectors recombinant proteins, live attenuated, and inactivated virus modalities, etc. Although immunogenicity and efficacy of these COVID vaccines were investigated, Covaxin (a vaccine code-named BBV152), an inactivated COVID-19 vaccine, has not been well studied yet. This study aimed to explore the interactions between biomolecules with vaccine adjuvants by analyzing molecular and protein–protein interactions of S protein, angiotensin-converting enzyme 2 (ACE2), and human serum albumin (HSA) with the ingredients of Covaxin (2-phenoxyethanol and imidazoquinolinone) by computational methods using Autodock Vina, Cluspro, and Swiss ADME. In addition, its drug-likeness property was investigated. The binding energies using Autodock Vina showed stronger interactions of 2-phenoxyethanol and imidazoquinolinone with viral surface protein, S protein, human cell membrane receptor ACE2, and drug carrier plasma HSA (−5.2, −5.3 and −5.3 kcal/mol; −8.5, −8.5 and −9.1 kcal/mol, respectively). The interaction between S protein with ACE2 in the presence of 2-phenoxyethanol and imidazoquinolinone hindered the S protein function by reducing the binding energy between these proteins. In addition, imidazoquinolinone may have the drug-likeness property based on pharmacokinetic and physicochemical parameters. These results suggest that the Covaxin vaccine, owing to these ingredients, may impart greater efficacy in averting the virus and thus it may be more effective in producing herd immunity. In conclusion, for the first time, this computational study predicts the possible useful effects of these two adjuvants of Covaxin in therapeutic and drug-likeness strategies against SARS-CoV-2.
first_indexed 2024-03-09T18:19:43Z
format Article
id doaj.art-820c2a520e254c7ba80298889ee90e90
institution Directory Open Access Journal
issn 2673-9879
language English
last_indexed 2024-03-09T18:19:43Z
publishDate 2022-08-01
publisher MDPI AG
record_format Article
series Future Pharmacology
spelling doaj.art-820c2a520e254c7ba80298889ee90e902023-11-24T08:25:42ZengMDPI AGFuture Pharmacology2673-98792022-08-012330631910.3390/futurepharmacol2030021A Computational Approach for Molecular Characterization of Covaxin (BBV152) and Its Ingredients for Assessing Its Efficacy against COVID-19Atala B. Jena0Asim K. Duttaroy1Centre of Excellence in Integrated Omics & Computational Biology, Utkal University, Bhubaneswar 751004, IndiaDepartment of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, 0317 Oslo, NorwaySARS-CoV-2 vaccination is a life-saving strategy for the entire population living in this pandemic. Several vaccines were developed using different platforms such as nucleic acids, viral vectors recombinant proteins, live attenuated, and inactivated virus modalities, etc. Although immunogenicity and efficacy of these COVID vaccines were investigated, Covaxin (a vaccine code-named BBV152), an inactivated COVID-19 vaccine, has not been well studied yet. This study aimed to explore the interactions between biomolecules with vaccine adjuvants by analyzing molecular and protein–protein interactions of S protein, angiotensin-converting enzyme 2 (ACE2), and human serum albumin (HSA) with the ingredients of Covaxin (2-phenoxyethanol and imidazoquinolinone) by computational methods using Autodock Vina, Cluspro, and Swiss ADME. In addition, its drug-likeness property was investigated. The binding energies using Autodock Vina showed stronger interactions of 2-phenoxyethanol and imidazoquinolinone with viral surface protein, S protein, human cell membrane receptor ACE2, and drug carrier plasma HSA (−5.2, −5.3 and −5.3 kcal/mol; −8.5, −8.5 and −9.1 kcal/mol, respectively). The interaction between S protein with ACE2 in the presence of 2-phenoxyethanol and imidazoquinolinone hindered the S protein function by reducing the binding energy between these proteins. In addition, imidazoquinolinone may have the drug-likeness property based on pharmacokinetic and physicochemical parameters. These results suggest that the Covaxin vaccine, owing to these ingredients, may impart greater efficacy in averting the virus and thus it may be more effective in producing herd immunity. In conclusion, for the first time, this computational study predicts the possible useful effects of these two adjuvants of Covaxin in therapeutic and drug-likeness strategies against SARS-CoV-2.https://www.mdpi.com/2673-9879/2/3/21SARS-CoV-2coronavirusCovaxinACE2HSAdrug–protein interaction
spellingShingle Atala B. Jena
Asim K. Duttaroy
A Computational Approach for Molecular Characterization of Covaxin (BBV152) and Its Ingredients for Assessing Its Efficacy against COVID-19
Future Pharmacology
SARS-CoV-2
coronavirus
Covaxin
ACE2
HSA
drug–protein interaction
title A Computational Approach for Molecular Characterization of Covaxin (BBV152) and Its Ingredients for Assessing Its Efficacy against COVID-19
title_full A Computational Approach for Molecular Characterization of Covaxin (BBV152) and Its Ingredients for Assessing Its Efficacy against COVID-19
title_fullStr A Computational Approach for Molecular Characterization of Covaxin (BBV152) and Its Ingredients for Assessing Its Efficacy against COVID-19
title_full_unstemmed A Computational Approach for Molecular Characterization of Covaxin (BBV152) and Its Ingredients for Assessing Its Efficacy against COVID-19
title_short A Computational Approach for Molecular Characterization of Covaxin (BBV152) and Its Ingredients for Assessing Its Efficacy against COVID-19
title_sort computational approach for molecular characterization of covaxin bbv152 and its ingredients for assessing its efficacy against covid 19
topic SARS-CoV-2
coronavirus
Covaxin
ACE2
HSA
drug–protein interaction
url https://www.mdpi.com/2673-9879/2/3/21
work_keys_str_mv AT atalabjena acomputationalapproachformolecularcharacterizationofcovaxinbbv152anditsingredientsforassessingitsefficacyagainstcovid19
AT asimkduttaroy acomputationalapproachformolecularcharacterizationofcovaxinbbv152anditsingredientsforassessingitsefficacyagainstcovid19
AT atalabjena computationalapproachformolecularcharacterizationofcovaxinbbv152anditsingredientsforassessingitsefficacyagainstcovid19
AT asimkduttaroy computationalapproachformolecularcharacterizationofcovaxinbbv152anditsingredientsforassessingitsefficacyagainstcovid19